How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix
Status:
Not yet recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
1. This strategy might suggest a therapeutic option to preserve ovarian function in young
patients among which locally advanced cancer cervix is common. Based on previous
studies, neoadjuvant irinotecan and cisplatin followed by radical hysterectomy and
adjuvant chemotherapy has the potential to improve the prognosis compared the concurrent
chemo-radiotherapy(CCRT).
2. To offer an alternative effective treatment line replacing concurrent chemo-radiotherapy
to avoid dramatic radiotherapy induced complications which might impede a safe
successful surgery.
2- To reduce the proportion of patients who will go for radiotherapy, consequently those
patients will still have a chance of probable less complicated surgery in case of local
recurrence.
3- This study will involve neo-adjuvant chemotherapy (NACT) in treating patients with stage
II-III cervical cancer for reducing tumor size, minimizing blood loss during surgery and
eradication of possible micro-metastasis.
4- To Improve the likelihood of achieving complete tumor resection after NACT. 5-
Investigators will further follow-up those patients for more detailed assessments to confirm
whether NACT can improve patients' prognoses, survival, quality of life, and the standard of
care.